Metformin vs Ozempic: different drugs, often used together
Not really rivals — metformin is the cheap, oral, first-line foundation; Ozempic (semaglutide) is a more potent injectable that adds greater glucose-lowering and real weight loss.
“Metformin vs Ozempic” is a slightly misleading framing, because the two aren’t competing for the same job. They’re different classes of drug, with different strengths, and in real diabetes care they’re frequently used together. The useful question isn’t which wins — it’s what each one is for.
Two different drugs, two different jobs
Metformin is a biguanide — an inexpensive oral pill that lowers glucose mainly by reducing the liver’s sugar output, with decades of safety data and a near-neutral effect on weight. Ozempic is semaglutide, a GLP-1 receptor agonist — a once-weekly injection that lowers glucose and powerfully reduces appetite. They lower blood sugar through completely different mechanisms, which is exactly why they combine well.
What the numbers show
In the SUSTAIN-2 trial, adding semaglutide to background therapy cut HbA1c by 1.3 to 1.6 percentage points and reduced body weight by 4.3 to 6.1 kg (at the 0.5 and 1.0 mg doses) — substantially more than the comparator.[1] Metformin’s glucose-lowering is real but more modest, and it doesn’t produce that kind of weight loss. So on raw potency for both blood sugar and weight, semaglutide wins clearly.
| Metformin | Ozempic (semaglutide) | |
|---|---|---|
| Class | Biguanide | GLP-1 receptor agonist |
| Route | Oral, daily | Injection, weekly |
| Glucose-lowering | Modest, reliable | Greater (−1.3 to −1.6 pts added) |
| Weight | ≈ neutral | Meaningful loss (4–6 kg) |
| Cost | Very low (generic) | High |
| Track record | Decades, first-line | Newer, potent |
The honest verdict
If you’re forced to compare them head to head, semaglutide is the more powerful drug for both blood sugar and weight — but metformin is cheaper, oral, weight-neutral, and carries a safety record semaglutide can’t yet match, which is why it remains a first-line foundation for many people.[1][2] For most patients the realistic path is metformin first, GLP-1 added when needed — not one instead of the other. Note this is Ozempic, the diabetes brand; for weight loss specifically the semaglutide brand is Wegovy (see Ozempic vs Wegovy). If metformin’s longevity angle interests you, see metformin and longevity; to compare GLP-1 options, our GLP-1 comparison tool and provider guide.
Reviewed against primary sources by the Aminoscope desk
Sources
- [1] Ahrén B, Masmiquel L, Kumar H, et al. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. PMID 28385659
- [2] American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care. PMID 38078590
Related tool
GLP-1 weight-loss comparison
See semaglutide, tirzepatide, retatrutide and the pipeline ranked by mean trial weight loss — every figure traced to its source.